Relmada Therapeutics (RLMD) Non Operating Investment Income (2020 - 2026)
Relmada Therapeutics (RLMD) reported Non Operating Investment Income of -$540097.0 for Q1 2026, down 446.81% year-over-year from $155731.0 in Q1 2025, and down 390.3% on a QoQ basis from $186045.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 7 years of Non Operating Investment Income data on file, last reported at -$540097.0 in Q1 2026.
- Quarterly Non Operating Investment Income fell 446.81% year-over-year to -$540097.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$297574.0 (down 366.28% YoY) and the FY2025 annual result came in at $398255.0, up 5813.21% from the prior year.
- Non Operating Investment Income declined to -$540097.0 in Q1 2026 per RLMD's latest filing, from $186045.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $3.8 million in Q4 2023 and bottomed at -$1.8 million in Q1 2022.
- The 5-year median for Non Operating Investment Income is -$45465.0 (2024), against an average of -$31301.8.
- The widest annual swing landed in 2022, when Non Operating Investment Income tumbled 1192.3%; it then surged 1260.84% in 2023.
- Tracing RLMD's Non Operating Investment Income over 5 years: stood at -$323120.0 in 2022, then surged by 1260.84% to $3.8 million in 2023, then tumbled by 107.39% to -$277068.0 in 2024, then jumped by 167.15% to $186045.0 in 2025, then plunged by 390.3% to -$540097.0 in 2026.
- Per Business Quant, the three latest RLMD Non Operating Investment Income figures stand at -$540097.0 (Q1 2026), $186045.0 (Q4 2025), and $70275.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -540,097.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -540,097.00 |
| Mar 31, 2026 | -540,097.00 |
| Dec 31, 2025 | 186,045.00 |
| Dec 31, 2025 | 186,045.00 |
| Sep 30, 2025 | 70,275.00 |
| Sep 30, 2025 | 70,275.00 |
| Jun 30, 2025 | -13,797.00 |
| Jun 30, 2025 | -13,797.00 |
| Mar 31, 2025 | 155,731.00 |
| Mar 31, 2025 | 155,731.00 |
| Dec 31, 2024 | -277,068.00 |
| Dec 31, 2024 | -277,068.00 |
| Sep 30, 2024 | 278,555.00 |
| Sep 30, 2024 | 278,555.00 |
| Jun 30, 2024 | -45,465.00 |
| Jun 30, 2024 | -45,465.00 |
| Mar 31, 2024 | 50,713.00 |
| Mar 31, 2024 | 50,713.00 |
| Dec 31, 2023 | 3.75 Mn |
| Dec 31, 2023 | 3.75 Mn |
| Sep 30, 2023 | -579,147.00 |
| Sep 30, 2023 | -579,147.00 |
| Jun 30, 2023 | -639,634.00 |
| Jun 30, 2023 | -639,634.00 |
| Mar 31, 2023 | 1.29 Mn |
| Mar 31, 2023 | 1.29 Mn |
| Dec 31, 2022 | -323,120.00 |
| Dec 31, 2022 | -323,120.00 |
| Sep 30, 2022 | -947,512.00 |
| Sep 30, 2022 | -947,512.00 |
| Jun 30, 2022 | -1.19 Mn |
| Jun 30, 2022 | -1.19 Mn |
| Mar 31, 2022 | -1.76 Mn |
| Mar 31, 2022 | -1.76 Mn |
| Dec 31, 2021 | -231,683.00 |
| Dec 31, 2021 | -231,683.00 |
| Sep 30, 2021 | 86,745.00 |
| Sep 30, 2021 | 86,745.00 |
| Jun 30, 2021 | -289,281.00 |
| Jun 30, 2021 | -289,281.00 |
| Mar 31, 2021 | -177,163.00 |
| Mar 31, 2021 | -177,163.00 |
| Dec 31, 2020 | -151,706.00 |
| Dec 31, 2020 | -151,706.00 |
| Sep 30, 2020 | 3,946.00 |
| Sep 30, 2020 | 3,946.00 |
| Jun 30, 2020 | 1.22 Mn |
| Jun 30, 2020 | 1.22 Mn |
| Mar 31, 2020 | -934,919.00 |
| Mar 31, 2020 | -934,919.00 |